<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00661921</url>
  </required_header>
  <id_info>
    <org_study_id>20070212</org_study_id>
    <nct_id>NCT00661921</nct_id>
  </id_info>
  <brief_title>A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Mutiple Dose, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous AMG 108 in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of blocking IL-1 signaling with AMG&#xD;
      108 in type 2 diabetes mellitus patients on glycemic control, as measured by change in HbA1c&#xD;
      from baseline to end of treatment (EOT).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Program Development discontinued&#xD;
  </why_stopped>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">October 2009</completion_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in HbA1c at week 14 (end of treatment)</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>40 mg AMG 108 Q2W</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>150 mg AMG 108 Q2W</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>75 mg AMG 108 Q2W</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Q2W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AMG 108</intervention_name>
    <description>IL-1 inhibitor, subcutaneous injection given every 2 weeks for the duration of the trial. Doses include 150 mg, 75mg, and 40 mg.</description>
    <arm_group_label>150 mg AMG 108 Q2W</arm_group_label>
    <arm_group_label>40 mg AMG 108 Q2W</arm_group_label>
    <arm_group_label>75 mg AMG 108 Q2W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>AMG 108 volume matching placebo</description>
    <arm_group_label>Placebo Q2W</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of T2DM ≥ 3 months at time of randomization&#xD;
&#xD;
          -  HbA1c of 7.0 - 9.5% (inclusive) at screening&#xD;
&#xD;
          -  ≥ 18 years of age at the time of randomization&#xD;
&#xD;
          -  BMI ≥ 25 kg/m2 and ≤ 45 kg/m2 at screening, and, per patient self-report, following&#xD;
             their regular weight maintenance or reduction diet for the management of diabetes for&#xD;
             at least 4 weeks prior to randomization&#xD;
&#xD;
          -  Fasting plasma glucose ≤ 240 mg/dL (13.3 mmol/L) at each of 2 determinations during&#xD;
             screening (samples taken at least 1 day apart)&#xD;
&#xD;
          -  No new therapy for the treatment of elevated blood pressure or dyslipidemia, use of&#xD;
             any weight loss medication (over the counter or prescription), or initiation of a&#xD;
             prescribed weight management or exercise program within 4 weeks before randomization&#xD;
&#xD;
          -  Subject is able and willing to comply with the study's visit requirement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of type 1 insulin-dependent diabetes&#xD;
&#xD;
          -  Significant signs and symptoms of uncontrolled hyperglycemia (ie, polyuria,&#xD;
             polydypsia, polyphagia), in the opinion of the investigator&#xD;
&#xD;
          -  History of significant weight gain or loss (+/- 5%) during the 4 weeks before&#xD;
             randomization&#xD;
&#xD;
          -  Triglycerides ≥ 400 mg/dL (4.5 mmol/L) and/or total cholesterol ≥340 mg/dL (8.7&#xD;
             mmol/L) at screening&#xD;
&#xD;
          -  Currently receiving or received within 60 days prior to screening any anti-diabetic&#xD;
             pharmaceutical therapy (eg, insulin) other than metformin and/or sulfonylurea. If&#xD;
             receiving metformin or sulfonylurea, doses must be stable for ≥ 60 days.&#xD;
&#xD;
          -  Uncontrolled hypertension defined as diastolic pressure &gt; 95 mmHg and/or systolic &gt;&#xD;
             170 mmHg during screening&#xD;
&#xD;
          -  Hepatic function test (alanine aminotranferase (ALT), aspartate aminotransferase&#xD;
             (AST), alkaline phosphatase, total bilirubin) results at screening &gt; 2 times the upper&#xD;
             limit of normal for the central laboratory&#xD;
&#xD;
          -  White blood cell count &lt; 3000 / μL, absolute neutrophil count (ANC) of &lt; 2500 / μL, or&#xD;
             platelet count of &lt; 125,000 / μL at screening&#xD;
&#xD;
          -  Any significant inflammatory, rheumatologic, or systemic autoimmune disease in the&#xD;
             opinion of the investigator&#xD;
&#xD;
          -  Evidence of active infection, recent infection, or chronic infection, requiring&#xD;
             treatment with anti-infectives, hospitalization or IV antibiotics within 4 weeks prior&#xD;
             to randomization&#xD;
&#xD;
          -  Active or latent Mycobacterium tuberculosis infection as defined by known positive PPD&#xD;
             or chest x-ray findings and failure to complete treatment with appropriate&#xD;
             chemoprophylaxis, or exposure to a person with active tuberculosis within 6 months&#xD;
             prior to randomization&#xD;
&#xD;
          -  Existence of non-healing wounds or ulcers&#xD;
&#xD;
          -  Known to be positive for hepatitis B surface antigen (HbsAg), hepatitis C virus (HCV)&#xD;
             or human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Estimated GFR (eGFR) at screening &lt; 30 mL/min as calculated via the MDRD equation&#xD;
             (Modification of Diet in Renal Disease study group)&#xD;
&#xD;
          -  Clinical evidence of current malignancy, with the following exceptions: basal or&#xD;
             squamous cell carcinoma of the skin, cervical intraepithelial neoplasia, prostate&#xD;
             cancer (if stable localized disease, with life expectancy of &gt; 3 years); or receiving&#xD;
             or has received chemotherapy and/or radiation therapy for treatment of a malignancy&#xD;
             within 6 months prior to randomization&#xD;
&#xD;
          -  Clinically significant cardiovascular disease (eg, heart failure of New York Heart&#xD;
             Association [NYHA] class 3 or 4), hematological abnormality, asthma, or chronic&#xD;
             obstructive pulmonary disease (eg, requiring oral or IV steroids), in the opinion of&#xD;
             the investigator&#xD;
&#xD;
          -  Receipt of any biologic or immunosuppressive therapy (experimental or commercial),&#xD;
             including anakinra (Kineret®) or any tumor necrosis factor (TNF) blocking agents (eg,&#xD;
             etanercept and infliximab), or live vaccines, within 3 months of randomization&#xD;
&#xD;
          -  Previously received AMG 108&#xD;
&#xD;
          -  Subject is evidently pregnant (eg, positive human chorionic gonadotropin [HCG] test),&#xD;
             is breast feeding, or is of child-bearing potential and not using adequate&#xD;
             contraceptive precautions, as determined by the investigator&#xD;
&#xD;
          -  Subject currently is enrolled in or has not yet completed at least 30 days since&#xD;
             ending other investigational device or drug study(s), or subject is receiving other&#xD;
             investigational agent(s)&#xD;
&#xD;
          -  Subject has any kind of condition (eg, psychiatric illness) or situation that, in the&#xD;
             investigator's opinion, compromises the ability of the subject to give written&#xD;
             informed consent, may put the subject at significant risk, may confound the study&#xD;
             results, or may interfere significantly with the subject's participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>April 17, 2008</study_first_submitted>
  <study_first_submitted_qc>April 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2008</study_first_posted>
  <last_update_submitted>September 4, 2018</last_update_submitted>
  <last_update_submitted_qc>September 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2018</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>AMG 108</keyword>
  <keyword>HbA1C</keyword>
  <keyword>glucose</keyword>
  <keyword>metformin</keyword>
  <keyword>sulfonylurea</keyword>
  <keyword>IL-1 Inhibitor</keyword>
  <keyword>biologic</keyword>
  <keyword>subcutaneous injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

